Cellular effects of paclitaxel-loaded iron oxide nanoparticles on breast cancer using different 2D and 3D cell culture models

被引:42
作者
Lugert, Stephan [1 ,2 ]
Unterweger, Harald [1 ]
Muehlberger, Marina [1 ]
Janko, Christina [1 ]
Draack, Sebastian [3 ]
Ludwig, Frank [3 ]
Eberbeck, Dietmar [4 ]
Alexiou, Christoph [1 ]
Friedrich, Ralf P. [1 ]
机构
[1] Univ Klinikum Erlangen, Else Kroner Fresenius Stiftung Professorship, SEON, Dept Otorhinolaryngol Head & Neck Surg, Erlangen, Germany
[2] Friedrich Alexander Univ Erlangen Nurnberg FAU, Erlangen, Germany
[3] TU Braunschweig, Inst Elekt Messtech & Grundlagen Elektrotech, Braunschweig, Germany
[4] Phys Tech Bundesanstalt Braunschweig & Berlin, Berlin, Germany
关键词
superparamagnetic iron oxide nanoparticles; SPIONs; three-dimensional cell culture; toxicity; flow cytometry; magnetic drug targeting; HUMAN SERUM-ALBUMIN; FLOW-CYTOMETRY; MAGNETIC NANOPARTICLES; DRUG-DELIVERY; MITOXANTRONE; BIOMARKERS; APOPTOSIS; SELECTION; TOXICITY; THERAPY;
D O I
10.2147/IJN.S187886
中图分类号
TB3 [工程材料学];
学科分类号
0805 ; 080502 ;
摘要
Background: Magnetic drug targeting (MDT) is an effective alternative for common drug applications, which reduces the systemic drug load and maximizes the effect of, eg, chemotherapeutics at the site of interest. After the conjugation of a magnetic carrier to a chemotherapeutic agent, the intra-arterial injection into a tumor-afferent artery in the presence of an external magnetic field ensures the accumulation of the drug within the tumor tissue. Materials and methods: In this study, we used superparamagnetic iron oxide nanoparticles (SPIONs) coated with lauric acid and human serum albumin as carriers for paclitaxel (SPIONLA-HSA-Ptx). To investigate whether this particle system is suitable for a potential treatment of cancer, we investigated its physicochemical properties by dynamic light scattering,. potential measurements, isoelectric point titration, infrared spectroscopy, drug release quantification, and magnetic susceptibility measurements. The cytotoxic effects were evaluated using extensive toxicological methods using flow cytometry, IncuCyte (R) live-cell imaging, and growth experiments on different human breast cancer cell lines in two- and three-dimensional cell cultures. Conclusion: The data showed that next to their high magnetization capability, SPIONLA-HSA-Ptx have similar cytostatic effects on human breast cancer cells as pure paclitaxel, suggesting their usage for future MDT-based cancer therapy.
引用
收藏
页码:161 / 179
页数:19
相关论文
共 48 条
[1]   Targeting of drug-loaded nanoparticles to tumor sites increases cell death and release of danger signals [J].
Alev, Magdalena ;
Egenberger, Laura ;
Muehleisen, Laura ;
Weigel, Bianca ;
Frey, Benjamin ;
Friedrich, Ralf P. ;
Poettler, Marina ;
Alexiou, Christoph ;
Janko, Christina .
JOURNAL OF CONTROLLED RELEASE, 2018, 285 :67-80
[2]   The MTT and Crystal Violet Assays: Potential Confounders in Nanoparticle Toxicity Testing [J].
Almutary, A. ;
Sanderson, B. J. S. .
INTERNATIONAL JOURNAL OF TOXICOLOGY, 2016, 35 (04) :454-462
[3]  
[Anonymous], DYN LIGHT SCATT INTR
[4]  
[Anonymous], 1995, HDB MAGNETIC MAT
[5]   Experimental and First-Principles Characterization of Functionalized Magnetic Nanoparticles [J].
Antipas, Georgios S. E. ;
Statharas, Eleftherios ;
Tserotas, Philippos ;
Papadopoulos, Nikolaos ;
Hristoforou, E. .
CHEMPHYSCHEM, 2013, 14 (09) :1934-1942
[6]  
Beenken S W, 2002, Minerva Chir, V57, P437
[7]   Sterically stabilized water based magnetic fluids:: Synthesis, structure and properties [J].
Bica, Doina ;
Vekas, Ladislau ;
Avdeev, Mikhail V. ;
Marinica, Oana ;
Socoliuc, Vlad ;
Balasoiu, Maria ;
Garamus, Vasil M. .
JOURNAL OF MAGNETISM AND MAGNETIC MATERIALS, 2007, 311 (01) :17-21
[8]   3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) (vol 28, pg 16, 2016) [J].
Cardoso, F. ;
Costa, A. ;
Senkus, E. ;
Aapro, M. ;
Andre, F. ;
Barrios, C. H. ;
Bergh, J. ;
Bhattacharyya, G. ;
Biganzoli, L. ;
Cardoso, M. J. ;
Carey, L. ;
Corneliussen-James, D. ;
Curigliano, G. ;
Dieras, V. ;
El Saghir, N. ;
Eniu, A. ;
Fallowfield, L. ;
Fenech, D. ;
Francis, P. ;
Gelmon, K. ;
Gennari, A. ;
Harbeck, N. ;
Hudis, C. ;
Kaufman, B. ;
Krop, I. ;
Mayer, M. ;
Meijer, H. ;
Mertz, S. ;
Ohno, S. ;
Pagani, O. ;
Papadopoulos, E. ;
Peccatori, F. ;
Penault-Llorca, F. ;
Piccart, M. J. ;
Pierga, J. Y. ;
Rugo, H. ;
Shockney, L. ;
Sledge, G. ;
Swain, S. ;
Thomssen, C. ;
Tutt, A. ;
Vorobiof, D. ;
Xu, B. ;
Norton, L. ;
Winer, E. .
ANNALS OF ONCOLOGY, 2017, 28 (12) :3111-3111
[9]   3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3) [J].
Cardoso, F. ;
Costa, A. ;
Senkus, E. ;
Aapro, M. ;
Andre, F. ;
Barrios, C. H. ;
Bergh, J. ;
Bhattacharyya, G. ;
Biganzoli, L. ;
Cardoso, M. J. ;
Carey, L. ;
Corneliussen-James, D. ;
Curigliano, G. ;
Dieras, V. ;
El Saghir, N. ;
Eniu, A. ;
Fallowfield, L. ;
Fenech, D. ;
Francis, P. ;
Gelmon, K. ;
Gennari, A. ;
Harbeck, N. ;
Hudis, C. ;
Kaufman, B. ;
Krop, I. ;
Mayer, M. ;
Meijer, H. ;
Mertz, S. ;
Ohno, S. ;
Pagani, O. ;
Papadopoulos, E. ;
Peccatori, F. ;
Pernault-Llorca, F. ;
Piccart, M. J. ;
Pierga, J. Y. ;
Rugo, H. ;
Shockney, L. ;
Sledge, G. ;
Swain, S. ;
Thomssen, C. ;
Tutt, A. ;
Vorobiof, D. ;
Xu, B. ;
Norton, L. ;
Winer, E. .
BREAST, 2017, 31 :244-259
[10]  
Chekhun S., 2013, Experimental Oncology, V35, P174